ADMA Biologics Files 8-K Report

Ticker: ADMA · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1368514

Adma Biologics, Inc. 8-K Filing Summary
FieldDetail
CompanyAdma Biologics, Inc. (ADMA)
Form Type8-K
Filed DateMar 5, 2024
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: disclosure, filing

Related Tickers: ADMA

TL;DR

ADMA Biologics filed an 8-K. Check for updates.

AI Summary

On March 4, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates that ADMA Biologics is making disclosures to the SEC, which could contain important updates for investors regarding the company's financial status or business operations.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not, in itself, indicate any new risks.

Key Players & Entities

  • ADMA BIOLOGICS, INC. (company) — Registrant
  • March 4, 2024 (date) — Date of Report
  • 001-36728 (company) — SEC File Number
  • 56-2590442 (company) — IRS Employer Identification No.
  • Ramsey, New Jersey (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

What is the exact name of the reporting company?

The exact name of the reporting company is ADMA BIOLOGICS, INC.

On what date was this report filed?

This report was filed on March 4, 2024.

What is the company's principal executive office address?

The company's principal executive office is located at 465 State Route 17, Ramsey, New Jersey 07446.

What is ADMA Biologics, Inc.'s SIC code?

ADMA Biologics, Inc.'s Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-03-05 16:05:30

Filing Documents

01

Item 7.01 Regulation FD. ADMA Biologics, Inc., a Delaware corporation (the "Company"), hereby furnishes the Corporate Presentation the Company expects to present, in whole or in part, and possibly with modifications, from time to time in connection with presentations to potential investors, strategic partners, industry analysts and others. The Corporate Presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein, and is available under the "Company Information" tab in the "Investors" section of the Company's website, located at www. admabiologics.com. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Corporate Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, except as may be required by the federal securities laws, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. The information furnished pursuant to this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the

01

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 ADMA Biologics, Inc. March 2024 Corporate Presentation. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. March 5, 2024 ADMA Biologics, Inc. By: /s/ Brian Lenz Name: Brian Lenz Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.